Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
Conditions
Interventions
Pembrolizumab
Carboplatin
+3 more
Locations
245
United States
University of South Alabama, Mitchell Cancer Institute ( Site 6033)
Mobile, Alabama, United States
Alaska Women's Cancer Care ( Site 6036)
Anchorage, Alaska, United States
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)
Orange, California, United States
John Muir Health Cancer Center ( Site 6028)
Walnut Creek, California, United States
Yale University School of Medicine ( Site 6009)
New Haven, Connecticut, United States
MedStar Washington Hospital Center ( Site 5005)
Washington D.C., District of Columbia, United States
Start Date
May 22, 2025
Primary Completion Date
May 24, 2032
Completion Date
May 24, 2032
Last Updated
April 23, 2026
NCT06340568
NCT06257264
NCT06253494
NCT06547840
NCT05990426
NCT05489211
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions